A Phase 1, Single-Dose, 3-Period Crossover Study to Evaluate the Relative Bioavailability of Two BCX7353 Capsule Formulations and to Evaluate the Effect of Food on BCX7353 Pharmacokinetics in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2017
At a glance
- Drugs BCX 7353 (Primary)
- Indications Hereditary angioedema
- Focus Pharmacokinetics
- Sponsors BioCryst Pharmaceuticals
- 24 Oct 2017 Status changed from active, no longer recruiting to completed.
- 10 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
- 03 Jul 2017 New trial record